Anuraag Suhrid Parikh, MD

The incidence of both melanoma and nonmelanoma skin cancers is on the rise; at the same time, our ability to treat skin cancers has vastly improved. Today there are many strategies for treating skin cancers which include radiation and light based therapy, topical and systemic chemotherapy, conventional surgery, and Mohs micrographic surgery, a highly effective treatment modality for skin cancers with aggressive behavior or located in cosmetically sensitive areas. In my practice, I strive to help my patients understand their diagnosis and work with them and their referring physician to choose an evidence-based therapeutic regimen that is tailored to their particular needs while achieving the highest possible cure rate, and the best functional and cosmetic outcome

Dr. Coromilas graduated cum laude from Columbia College, Columbia University and earned her medical degree from Columbia University Vagelos College of Physicians and Surgeons, where she was inducted into Alpha Omega Alpha (AOA) Honor Medical Society and The Gold Humanism Honor Society (GHHS). She completed her Internal Medicine residency at Massachusetts General Hospital, followed by Dermatology residency at Columbia University/New York Presbyterian Hospital. She is board certified in Internal Medicine and Dermatology. After completion of her Internal Medicine and Dermatology training, Dr. Coromilas completed the Complex Medical Dermatology Fellowship at University of Pennsylvania under the mentorship of Dr. Misha Rosenbach. She specializes in providing care for patients with complex medical dermatologic conditions such as granulomatous skin conditions, hidradenitis suppurativa, cutaneous complications of inflammatory bowel disease, pyoderma gangrenosum, and autoimmune conditions of the skin such as lupus, dermatomyositis, and autoimmune blistering disorders. She has an interest in caring for patients with cutaneous adverse effects of oncologic therapy including immune related adverse events due to immune checkpoint inhibitors. Dr. Coromilas is a Fellow of the American Academy of Dermatology (AAD), as well as a member of the Medical Dermatology Society, Society of Dermatology Hospitalists, and Women's Dermatologic Society (WDS). She has authored numerous peer-reviewed publications and has spoken at local and national dermatology conferences

Brian Marr, MD heads the Ophthalmic Oncology Service at the Harkness Eye Institute. He has comprehensive experience in the diagnosis, treatment, and management of ocular tumors including intraocular tumor resection, laser, radiation, and chemotherapy procedures. He has helped devise thousands of complex treatments for tumors of the eye, eyelid, orbit, and conjunctiva for his adult, children, and infant patients. Currently, Dr. Marr is a collaborator on a Columbia University clinical trial for a first-of-its-kind, new class of drug treatment for uveal melanoma. Dr. Marr is a board-certified ophthalmologist whose work has centered around ophthalmic oncology since 2000. One of the very few ocular oncologists trained in all aspects of eye cancer, Dr. Marr's clinical experience in treating these diseases is among the most extensive in the United States. His interest and experience in ophthalmic oncology began during an eight-year tenure in the Ocular Oncology Service at the Wills Eye Hospital in Philadelphia. There, he gained extensive experience treating intraocular tumors, and tumors of the eyelid, orbit, and conjunctiva in children and adults. It was there that Dr. Marr developed and improved many surgical procedures used to cure cancers of the eye, successfully treated thousands of patients, and helped their families though their battle with eye cancer. Next, Dr. Marr moved on to Memorial Sloan Kettering Cancer Center, where he remain for nine years, starting in 2008. Dr. Marr has some of the greatest experience with intra-arterial chemotherapy for treating retinoblastoma in the country, if not the world, as well as all other forms of retinoblastoma treatment. He has been a key member of many multidisciplinary surgical teams, treating advanced skull base tumors and complex facial skin lesions. He has developed a strong belief and treatment philosophy that the best research be used to help his patients, rather than his best patients be used to help his research. The field of ophthalmic oncology encompasses many rare conditions and his experience helps his patients get the best care and results as quickly as possible. Dr. Marr lectures and consults across the US and abroad, and has authored numerous research articles in the field of ocular oncology. He is the principal investigator in a first-in-class drug study for treating primary uveal melanoma, in an international, multi-center trial. He also volunteers his medical expertise in underserviced parts of the world, such as Nigeria and Indonesia, and has helped train physicians in more than 20 countries. Dr. Marr’s efforts as a contributor to ongoing education in ocular oncology have been recognized by the American Academy of Ophthalmology, where he now serves as chief editor of the Academy’s Oncology and Pathology’s One network.